Two-year regional grey and white matter volume changes with natalizumab and fingolimod.

Paolo Preziosa Maria Assunta RoccaElisabetta PaganiLoredana StorelliMariaemma RodegherLucia MoiolaMassimo Filippi

Published in: Journal of neurology, neurosurgery, and psychiatry (2020)

Natalizumab and fingolimod are associated with heterogeneous temporal and regional patterns of GM and WM atrophy progression. Compared with natalizumab, fingolimod-treated patients experience accelerated GM and WM atrophy in the cerebellum, while both drugs show minimal regional volumetric differences in supratentorial regions.

Keyphrases

multiple sclerosis
white matter
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis